Pedro Fragoso Costa

⁹⁰ Y-FAPI-46 Radiopharmaceutical Therapy in Sarcoma and Other Solid Tumors: An Updated Cohort Analysis

⁹⁰Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous Tumors

Thyroid Hormone Withdrawal Yields Higher ¹³¹ I Absorbed Dose to Metastases Than rhTSH Stimulation in Differentiated Thyroid Cancer: Evidence from a Large ¹²⁴ I PET/CT Dosimetry Cohort

Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor

The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue,⁶⁸Ga-FAPI-46 PET Data, and Survival Data

Near‐infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: A single center experience

Joint EANM/SNMMI guideline on radiomics in nuclear medicine

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

First experiences with dynamic renal [68Ga]Ga-DOTA PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate

Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice

Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer

Direct proton range verification using oxygen-18 enriched water as a contrast agent

Towards using secondary gamma-rays from proton-induced radioactivation of titanium implants for off-line field verification

Can a ToF-PET photon attenuation reconstruction test stopping-power estimations in proton therapy? A phantom study

Estimating the modulating effect of lung tissue in particle therapy using a clinical CT voxel histogram analysis

Technologist Approach to Global Dose Optimization